The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), completed in 2023 with over 17,600 participants, demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity but without diabetes
Fetching molecular profile BPC-157/TB-500/GHK-Cu BlendAlso known as: BTG Blend, Body Protection Compound 157, Thymosin Beta-4, Copper Peptide, GHK-Cu Mechanism of Action BPC-157 promotes tissue healing primarily via vascular endothelial growth factor (VEGF) modulation, supporting angiogenesis and tissue restoration
DSIP has no side effects. Some small insomnia studies reported no significant adverse effects
The PDCOs maintained a 94% genomic similarity to the original tumor and generated chemogram (always presented in the form of heatmaps and dose-response curves) for 25 drug tests within 6 weeks
Appl Microbiol Biot 94(5):13131319